Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

ot be predictive of future data or results; the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies; and risks related to the conduct of Sunesis' clinical trials and manufacturing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2007, Sunesis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Contacts:                        Media Contact:
    Sunesis Pharmaceuticals, Inc.    Invigorate Communications
    Eric Bjerkholt                   Monique Greer
    650-266-3717                     415-946-1075


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... rate of HIV infection and the number of deaths due ... positive rate across the globe. It has been estimated that ... 1.5 in 2013, with the rates for children being even ... the infection rates has been the improved access to antiretroviral ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
Breaking Biology Technology:Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... ON , Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences ... financial results for the second quarter of fiscal 2010, ended ... numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., ... during the second quarter," said David Allan , Chairman ...
... , DENVER and NEW ORLEANS , Feb. ... worldwide developer and marketer of diagnostic test kits, and Tulane ... to combat viral hemorrhagic fever (VHF), an effort that will generate ... the life of the contract. , The National Institutes of ...
... , Feb. 8 Neurocrine Biosciences, Inc. (Nasdaq: ... Ph.D. to its Board of Directors effective immediately. He is the ... Executive Chairman of Biogen Idec, Inc. , "We are very pleased ... said Joseph A. Mollica , Ph.D., Chairman of the Board ...
Cached Biology Technology:YM BioSciences reports second quarter 2010 operational and financial results 2YM BioSciences reports second quarter 2010 operational and financial results 3YM BioSciences reports second quarter 2010 operational and financial results 4YM BioSciences reports second quarter 2010 operational and financial results 5YM BioSciences reports second quarter 2010 operational and financial results 6YM BioSciences reports second quarter 2010 operational and financial results 7YM BioSciences reports second quarter 2010 operational and financial results 8YM BioSciences reports second quarter 2010 operational and financial results 9YM BioSciences reports second quarter 2010 operational and financial results 10YM BioSciences reports second quarter 2010 operational and financial results 11YM BioSciences reports second quarter 2010 operational and financial results 12Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors 2
(Date:8/20/2014)... The sweet and salty aroma of sunscreen and seawater ... are now reporting that the idyllic beach vacation comes ... off skin and into the sea, they can become ... are the main course for many other marine animals. ... Science & Technology . , Antonio Tovar-Sanchez and David ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... Virginia Tech,s Wu Feng has built upon a National ... in the Cloud" program, and synergistically complemented it with ... the Air Force on "big computing" for mini-drones and ... Institutes of Health on "big data" for the life ... aspects from each grant, he was able to tell ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... discovered that very small chemical changes to dietary flavonoids cause ... for their impact on the human immune system., Plants are ... an average leaf for example, produces around 20,000. Many ... are already known to have medicinal properties with effects on ...
... and government, industry and health professionals will gather in ... the research supporting the health benefits of mushrooms ... produce aisle and often thought of as a vegetable ... The Mushrooms and Health Summit, held at the ...
... cholesterol levels and reducing the risks of cardiovascular disease, but ... The FASEB Journal suggests that they may extend ... which telomeres shorten, a key factor in the natural aging ... of statins, as an anti-aging therapy. "By telomerase activation, ...
Cached Biology News:Little changes -- large effects 2World's scientists, researchers and nutrition experts convene to explore the benefits of mushrooms 2
...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
... Point Osmometer for 10 L sample. ... including pediatric, neonatal, geriatric, general adult, ... Calibration with 2 or 3 user-selected ... and software for statistical analysis and ...
Biology Products: